Actemra®

STOP-Uveitis randomised 37 patients to 4 mg/kg or 8 mg/kg intravenous tocilizumab every 4 weeks to month 6. Its primary endpoint was safety, and repeated infusions were well tolerated; the sight measures below are all secondary. Among those with room for it, 43.5% achieved a 2-step reduction in vitreous haze; mean visual acuity improved 8.22 letters and mean central macular thickness fell 83.88 micrometres. Read the design before the numbers: the trial compared two doses of tocilizumab against each other, with no placebo or active control arm, so it shows the drug is tolerated and that treated eyes improved, not that it beats an alternative.